AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Physiologically based pharmacokinetic modelling to determine pharmacokinetic alterations driving ritonavir exposure changes in aging people living with HIVView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019An exploration of adherence measures to detect recent changes in Truvada® dosing patternsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Tenofovir-diphosphate in PBMC following increasing TAF vs. TDF dosing under directly observed therapyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Pharmacokinetics of tenofovir alafenamide 25 mg with PK boosters during pregnancy and postpartumView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Low isoniazid concentrations in pregnant and postpartum women treated for tuberculosis irrespective of efavirenz-based ART co-treatmentView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Pharmacokinetics of atazanavir boosted with cobicistat during pregnancy and postpartumView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Infant exposure to dolutegravir through placental and breastmilk transfer: A population PK analysis of DolPHIN-1View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Infectious disease action plan for the global accelerator for paediatric formulations (GAP-f)View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Effect of CYP2b6 metabolizer status on levonorgestrel pharmacokinetics when combined with efavirenz-based antiretroviral therapyView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Drugs abuse and chemsex: A new challenge for antiretroviral drug-drug interactionView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Changes in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website.View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019The initial Phase 1 evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next generation HIV maturation inhibitor, as assessed in healthy subjectsView Abstract
